Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORA102
- Development stage
- Phase 2
- Lead developer
- Ora Bio
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
ORA102 is an investigational drug developed by Ora Bio Ltd. It is being evaluated in a Phase I/II pilot study for the treatment of neovascular Age-related Macular Degeneration (AMD) when combined with Avastin (Bevacizumab). The drug is administered via intravitreal injections.
- Other names
- acitretin
Beyond the preview
Go deeper on ORA102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORA102.